Whispers from the peptide communities.

Peptide histamine reactions: it's usually not an allergy

Most peptide "allergic" reactions are not allergies. Many peptides directly activate MRGPRX2, a mast cell receptor that triggers histamine release without any immune sensitisation — which is why reactions can happen on first exposure. And if you react to several unrelated peptides from different suppliers, the likeliest culprit is the bacteriostatic water, not the peptides.

Lilly sues six retatrutide sellers: what the crackdown means

On 12 August 2026 Eli Lilly filed six lawsuits against US companies allegedly selling black-market retatrutide, and referred more than 200 individuals and entities to the FDA, Justice Department, state attorneys general and licensing boards. Retatrutide has not even had an FDA application submitted yet. Days later it appeared for sale on Amazon.

Tirzepatide and the 45% mortality claim: why two studies disagree

A BMJ study reported tirzepatide cutting all-cause mortality by 45% versus sitagliptin. The randomised trial of the same drug, SURPASS-CVOT, found it merely noninferior to dulaglutide. Both are real. The gap is study design — and the giveaway is that the observational study also found a 60% drop in infection deaths.

Does retatrutide really do the job of six peptides?

Every individual claim is supported by trial data. Retatrutide does lower blood pressure, lipids, glucose and inflammatory markers, and improves sleep apnoea. But these are not six independent drug actions — they are one very large weight loss and five of its well-known consequences. And retatrutide is not approved anywhere.

Zero-peptide vials and "Faketide": the 2026 counterfeit wave explained

Vials sold as peptides are testing with no active ingredient at all — filled instead with hydroxyacetophenone, a cheap ketone. Independent labs disagreed on which isomer for months before comparing data. Separately, the owner of Paradigm Peptides was sentenced to 70 months in federal prison for forged lab certificates and selling testosterone labelled as SARMs.

Topical rapamycin for hair loss: good mechanism, no trial

The mechanism is real: mTORC1 activity negatively regulates human hair follicle growth, so inhibiting it is a rational target. But no published randomised trial has tested topical rapamycin as a standalone treatment for androgenetic alopecia, and the commercial products selling it combine it with finasteride and minoxidil.

Methylene blue: the evidence, and the SSRI interaction nobody mentions

Methylene blue is a potent MAO-A inhibitor, and combining it with an SSRI can cause life-threatening serotonin syndrome. That risk is rarely mentioned where it is sold as a nootropic. The mechanism is real, but the human cognitive evidence is one 26-person fMRI study, and the Phase III Alzheimer's trials failed.

BPC-157 healing timelines: animal vs human evidence reviewed

A 2025 systematic review screened 544 published papers on BPC-157 and included 36. Of those, 35 were animal or cell studies and one involved humans. That ratio is the single most important fact about this compound: the healing timelines everyone quotes come from rodents, and essentially none of them have been reproduced in people.